צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: CNS Pharmaceuticals (CNSP)

CNS Pharmaceuticals aims to carve out a niche in glioblastoma treatment, targeting neuro-oncology centers. The TTM annual revenue change on the GURU.Markets daily chart reflects progress toward this goal, with the metric currently at 0.00. However, growth is constrained by the high complexity of the team's scientific research and the risks of trial failures, which necessitate continuous share issuance.
CNS Pharmaceuticals, Inc. (CNSP) - פילוחי מדדים ודוחות פיננסיים

For the biotechnology company CNS Pharmaceuticals (CNSP), this indicator reflects the revenue growth rate over a rolling year, allowing for an assessment of the business's commercial resilience against the pre-commercial risks of the drug Berubicin. Analyzing the year-over-year sales dynamics over the last 12 months TTM helps investors distinguish random spikes from the systemic development of the model, determining the issuer's actual viability during periods of cooling market demand.